


Toronto Lymphoma Conference 2023

Meeting Program

November 3, 2023
Toronto, ON



**A DEDICATED FORUM
FOR CANADIAN CLINICIANS
ON THE MANAGEMENT OF
HEMATOLOGIC DISEASE**



Canadian Hematology Today

2024 Symposium on B-Cell Malignancies

April 19 & 20, 2024

Toronto, ON

Current updates on the latest developments in managing B-cell malignancies in Canadian practice, with section topics including:

- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma

Mark your calendar!

More information coming soon.

About Canadian Hematology Today

Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.

The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians, nurses and hospital pharmacists across Canada. It features peer-edited articles that present robust clinical perspectives and practical insights into disease management.

Past issues of Canadian Hematology Today are archived digitally at canadianhematologytoday.com.

To subscribe to the journal, please visit catalytichealth.com/subscribe.



Canadian Hematology Today
Science for the Real World

Conference Objectives

- Provide current and high-quality information on the latest developments in the management of lymphoproliferative disease
- Create collegial learning opportunities to enable clinicians to share real-world experience and to directly apply new insights to their practice
- Foster discussions that allow for the sharing of knowledge and experience among delegates and industry representatives
- Respond to emerging professional needs for specific and in-depth information on the latest therapies for lymphoproliferative disease in the Canadian market

Our Sponsors

Leaders



Supporters

abbvie

AstraZeneca 

janssen 

 Roche

 sobi

 Seagen®

Conference Agenda

Time	Session	Speaker
7:00 AM	Breakfast (60 mins)	
8:00 AM	Introduction & Welcome	Dr. John Kuruvilla & Dr. Peter Anglin
8:10 AM	What is the SOC for POD24 FL	Dr. Dai Chihara <i>MD Anderson Cancer Center</i>
8:30 AM	BiTEs and CARTs in RR-FL	Dr. Ronan Foley <i>McMaster University</i>
8:50 AM	Panel	
9:05 AM	Overview of the Treatment of PTCL-NOS	Dr. Matthew Lunning <i>University of Nebraska Medical Center</i>
9:25 AM	Management of Rare PTCL Subtypes	Dr. Anca Prica <i>Princess Margaret Cancer Centre</i>
9:45 AM	Panel	
10:00 AM	Health Break (15 mins)	
10:15 AM	Evolving Primary Therapy Approaches in DLBCL	Dr. Jason Westin <i>MD Anderson Cancer Center</i>
10:35 AM	What is new in CART for DLBCL	Dr. Jakub Svoboda <i>University of Pennsylvania</i>
10:55 AM	Bispecific Antibodies in RR-DLBCL	Dr. Krish Patel <i>Swedish First Hill Hospital, Seattle, WA</i>
11:15 AM	Panel	
11:30 AM	Lunch (60 mins)	

Time	Session	Speaker
12:30 PM	The Shifting Sands of Primary Treatment of Advanced cHL	Dr. Ann LaCasce <i>Dana-Farber Cancer Institute</i>
12:50 PM	Optimizing Treatment of RR-cHL	Dr. Michael Crump <i>Princess Margaret Cancer Centre</i>
1:10 PM	Panel	
1:25 PM	The Evolution of Primary Treatment in MCL	Dr. John Kuruvilla <i>Princess Margaret Cancer Centre</i>
1:45 PM	Positioning Novel Therapy in RR-MCL	Dr. Kami Maddocks <i>Ohio State University Comprehensive Cancer Center</i>
2:05 PM	Panel	
2:20 PM	Health Break (15 mins)	
2:35 PM	CLL Frontline Therapy: Fixed Duration vs. Treat to Progression	Dr. Abi Vijenthira <i>Princess Margaret Cancer Centre</i>
2:55 PM	How to treat CLL after BTKi and BCL2i	Dr. Versha Banerji <i>CancerCare Manitoba</i>
3:15 PM	Richter's Syndrome: State-of-the-Art Management	Dr. Tanya Siddiqi <i>City of Hope National Medical Center, Duarte, CA</i>
3:30 PM	Panel	
3:45 PM	Closing Remarks	Dr. John Kuruvilla & Dr. Peter Anglin
4:00 PM – 6:00 PM	Networking Reception	

Scientific Steering Committee



**John Kuruvilla,
MD, FRCPC**

Dr. John Kuruvilla is a Professor of Medicine at the University of Toronto and a hematologist in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto. He is a member of the Lymphoma, Autologous Transplant and Immune Effector Cell Therapy programs. Dr. Kuruvilla's research interest is the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group (CCTG) as well as the Chair of the Scientific Advisory Board of Lymphoma Canada.



**Peter Anglin,
MD, MBA, FRCPC**

Dr. Peter Anglin's clinical focus remains in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. He has also developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients. He continues to serve in an advisory capacity to a number of pharmaceutical and health-related organizations. He remains the medical director of CarePath, a cancer navigation and support service supporting Cancer Care Ontario and Ontario cancer patients.

Symposium Faculty




Dr. Versha Banerji
MD

Dr. Versha Banerji obtained her MD and residency training in internal medicine and hematology at the University of Manitoba. She then completed a post-doctoral fellowship in translational research at the Harvard Cancer Centre/Dana-Farber Cancer Institute and the Broad Institute of MIT. She is a senior scientist at the CancerCare Manitoba Research Institute, Associate Professor at the University of Manitoba, and a clinician-scientist at CancerCare Manitoba. She co-leads the CLL clinic and is involved in several clinical trials and population-based treatment studies. As co-chair of the CLL research program she manages a multi-disciplinary research team in clinical, fundamental and translational research. Her own laboratory is evaluating mitochondrial bioenergetics and function as a measure of cancer cell metabolism.



Dr. Dai Chihara
MD, PhD

Dr. Dai Chihara, MD, PhD is an Assistant Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center in Houston, TX USA. Dr. Chihara received his MD degree from Kobe University and completed residency, fellowships in hematology and oncology both in Japan and the United States. Dr. Chihara focuses on clinical research of lymphoma from outcomes research to clinical trials with particular focus on aggressive and indolent B-cell lymphomas. He has led multiple research projects utilizing clinical data and population-based cancer registry data to identify high risk populations with poor outcomes. Dr. Chihara is working on development of experimental therapeutics and discovering novel trial design and biomarkers in lymphoma through clinical trials to address unmet need at MD Anderson Cancer Center. Dr. Chihara is a member of American Society of Hematology, the American Society of Clinical Oncology, and the Japanese Society of Hematology.



Dr. Michael Crump MD, FRCPC

Dr Michael Crump is a Hematologist in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, and Professor of Medicine at the University of Toronto. He was the co-chair of the Hematology Site Group of the CCTG for many years and the co-chair of the Lymphoma working group. His research interests include the development of new therapies for lymphomas including bispecific antibodies and chimeric antigen receptor (CAR) T cells and the application of autologous stem cell transplantation.



Dr. Ronan Foley MD, FRCPC

Dr. Ronan Foley, MD, FRCPC, is a clinical hematologist with an active practice in malignant hematology at the Juravinski Cancer Centre. He is Director of the Stem Cell Laboratory. Dr. Foley is a Professor of Pathology and Molecular Medicine at McMaster University, Past-President of CBMTG, a Director of the Clinical Trials Network and a member of the NIH Consensus Panel for the Diagnosis and Classification of Chronic Graft vs. Host Disease along with several other affiliations. Other activities include board membership on OCREB and panel chair for the CIHR CBT panel. Dr. Foley's current research focus is the development of therapeutic cell-based autologous vaccines. He has held grants with CANVAC, OICR, CIHR, OCRN, and CBCRA.



Dr. Ann LaCasce MD

Dr. Ann S. LaCasce earned her medical degree from Tufts University School of Medicine. She completed training in internal medicine at Brigham and Women's Hospital in Boston, where she later served as a Chief Medical Resident. After her fellowship in medical oncology at Dana-Farber/Partners Cancer Care, she pursued formal training in clinical investigation, earning a Master in Medical Science from Harvard/MIT Division of Health Sciences and Technology. Since 2003, she has been a member of the

Lymphoma Program at Dana-Farber where she performs clinical research. She has a longstanding interest in medical education, and is the Program Director of the Dana-Farber/Mass General Brigham Fellowship in hematology/oncology. In addition, she co-directs the Center for Adolescent and young Adult Oncology at Dana-Farber. She is an Associate Professor of Medicine at Harvard Medical School. She is Chair of the Lymphoma Research Foundation Scientific Advisory Board and serves on the ABIM Medical Oncology Board, the National Comprehensive Cancer Network's Lymphoma Guideline Panel, and the Alliance Lymphoma Committee.



Dr. Matthew Lunning MD

Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center. He serves the Department of Internal Medicine as the Associate Vice Chair of Research. He recently was appointed as an Assistant Vice Chancellor of Clinical Research and elected to serve on the Nebraska Medicine Medical Executive Committee as an at-large member. He received his medical

degree from Des Moines University in 2006. Dr. Lunning completed his internal medicine residency at UNMC where he served as Chief Medical Resident. He completed his Hematology/Oncology fellowship and served as the Hematology Chief Fellow at Memorial Sloan-Kettering Cancer Center. Dr. Lunning returned to UNMC in 2013 and has been active in clinical research, research mentoring, education, and patient care and was the recipient of the Distinguish Scientist Award in 2019. Dr. Lunning has served on several National Comprehensive Cancer Network's guidelines committees including the Immunotherapy Toxicity & T-cell lymphoma panels. He has served as an invited member of ASCO's Cancer Education Committee on the Non-Hodgkin Lymphoma. He is the co-organizer of the Pan Pacific Lymphoma Conference.



Dr. Kami Maddocks MD

Dr. Kami Maddocks is a Professor of Clinical Internal Medicine and Director of the Lymphoma Program in the Division of Hematology. She specializes in treating patients with B-cell lymphomas. Dr. Maddocks conducts research evaluating new-targeted therapies for these lymphomas, with a particular interest in mantle cell lymphoma and diffuse large B-cell lymphoma. Dr. Maddocks is an investigator on several clinical trials in lymphoma, evaluating non-chemotherapeutic approaches to the treatment of lymphoma and the role of minimal residual disease in predicting outcomes and making therapeutic decisions. She serves on the Alliance Lymphoma Committee, serving as the Alliance Chair on two MCL trials through the AFT and NCTN. In collaboration with colleagues at OSU and Cornell, they were awarded an LLS and NCI P01 to study functional genomics in mantle cell lymphoma therapy and mechanisms of resistance.



Dr. Krish Patel MD

Dr. Krish Patel, MD is a clinical investigator, Director of the Lymphoma Program, and Director of Hematologic Malignancies and Cellular Therapy at the Swedish Cancer Institute (SCI) in Seattle, Washington. Dr. Patel received his medical degree from Duke University School of Medicine, where he also completed post graduate training in internal medicine, hematology, and medical oncology. In 2016, he joined the Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy as a specialist in the care of patients with lymphomas and CLL.

Since 2022, Dr. Patel has served as the Director of Hematology and Cellular Therapy to oversee the continued growth of SCI's clinical and research programs in all hematologic diseases and broader strategy in growth of cellular therapy, including applications of cellular therapy in solid tumor malignancies and non-oncologic diseases.

Clinically, Dr. Patel specializes in all aspects of care of patients with lymphomas and CLL and is a specialist in the therapeutic use of cellular and non-cellular immunotherapies. He has a specific research focus in the early stage development of novel targeted agents, immunotherapies, and engineered cellular therapies to advance care for patients with lymphoid malignancies. He is an active principal investigator for numerous therapeutic clinical trials, with a focus on phase I and II studies in lymphomas, CLL, and cellular therapies. Dr. Patel is also a member of the Paul G. Allen Research Center at SCI, serving as a co-founding member of the Center for Immuno-oncology, where he collaborates on translational research related to immunotherapy in hematologic diseases.



Dr. Anca Prica **MD**

Dr. Anca Prica is a staff hematologist at Princess Margaret Cancer Centre, and associate professor in the division of hematology at University of Toronto, appointed in 2014. She is currently the site lead of the lymphoma and myeloma program at Princess Margaret Cancer Centre. She did her initial medical training in Toronto, and her clinical training in Internal Medicine and Hematology in the University of Toronto Program. She then did a 2 year fellowship in Malignant Hematology at the Sunnybrook Health Sciences Centre and a Masters in Health Research Methodology at McMaster University, with research interests in quality of life and economic evaluations. Her clinical work focuses in both lymphoproliferative and plasma cell disorders, as well as autologous stem cell transplantation and CAR-T therapy. Her research interests focus on health services research, particularly economic evaluations and decision analyses for oncologic questions, examining resource use and cost of care, as well as toxicity of chemotherapies, and their effects on quality of life and caregiver burden.



Dr. Tanya Siddiqi **MD**

Dr. Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphomas. She is the Medical Director of Lymphoma at City of Hope Orange County and the Director of the CLL Program in the Department of Hematology/HCT.

In addition to her clinical practice, Dr. Siddiqi is also the principal investigator of several national and international clinical trials evaluating the role of targeted therapies, including CAR T cell therapy, and other novel agents in diseases like CLL and B-cell non-Hodgkin lymphomas. As a result, she has been part of many major presentations and publications in recent years, some of which have led to FDA approvals of agents and have been practice changing.

Dr. Siddiqi earned her medical degree in 2000 at the Aga Khan University Medical College in Karachi, Pakistan. Afterwards, she completed an internal medicine residency at the University of Connecticut Health Center, followed by two fellowships: Hematology/Oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston, MA) and Hematopoietic Cell Transplantation at City of Hope. Dr. Siddiqi is a member of the Toni Stephenson Lymphoma Center, the Gehr Family Center for Leukemia Research, and the Immunotherapy Disease Team at City of Hope.



Dr. Jakub Svoboda
MD

Dr. Jakub Svoboda received his medical degree from Yale School of Medicine and completed a hematology-oncology fellowship at the University of Pennsylvania. He is currently an Associate Professor of Medicine at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, U.S.A. His research activities focus on development of novel treatments for patients with lymphoma. He has been an investigator on multiple clinical trials including first-in-human studies using cellular and immune-based therapies. He also serves as a representative on a number of national committees including NCCN and BMT CTN. He received several professional awards including the John Glick Teaching Award and the Headstrong Foundation Award for Clinical Excellence.



Dr. Abi Vijenthira
MD

Dr. Abi Vijenthira is an Associate Professor of Medicine at the University of Toronto and staff hematologist in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. Dr. Vijenthira received her medical degree from the University of Ottawa and completed her Internal Medicine and Hematology residencies at the University of Toronto. She completed fellowships in Lymphoma at Princess Margaret and in CLL at Dana Farber Cancer Institute, and a Master of Science in Clinical Epidemiology at Harvard University. Dr. Vijenthira's clinical practice involves the treatment of patients with lymphomas. Her research interests include population-based outcomes and health services research.



Dr. Jason Westin
MD, FACP

Dr. Jason Westin is Professor, Director of Lymphoma Clinical Research, and Section Chief of Aggressive Lymphoma at MD Anderson Cancer Center in Houston, TX, USA. He writes and runs innovative and practice changing clinical trials, including the Smart Start and Smart Stop trials, and is an expert in CAR T-cell therapy and drug development.

Symposium Sponsorship

The 2023 Toronto Lymphoma Conference has been made possible through the support of our sponsors, leaders in hematologic care in Canada.

Leaders



BeiGene

At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity. Our vision is to transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world. Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo. As part of our global clinical development program, we're enrolling patients in 40+ countries and geographies to participate in our clinical trials.

CANCER HAS NO BORDERS. NEITHER DO WE.



Incyte

Incyte is a global biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and R&D drive Incyte's business and its commitment to making a difference in the lives of patients through scientific discovery. We have an experienced team with a track record of success, and our goal is to create first-in-class and best-in-class therapeutics to meet serious unmet medical needs. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, United States, Incyte has operations in North America, Europe and Asia.

For more information, please visit [incyte.com](https://www.incyte.com).

Leaders Cont.



Kite Pharma

Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.

Supporters



AbbVie

Research and innovation are the cornerstones of our business. We focus on discovering, developing, and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. This includes Immunology, Oncology, Neuroscience and Virology, Women's health, and General medicine.

For more information, please visit abbvie.ca.



Janssen

Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. We focus on the following areas of medicine: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Learn more at <http://www.janssen.com/canada>.

Supporters Cont.



AstraZeneca is a global, innovation-driven biopharmaceutical business with a focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular, Renal and Metabolic disease; Oncology; and Respiratory & Immunology. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ roughly 950 employees across the country and our headquarters are located in Mississauga, Ontario. The company invested \$145 million in Canadian research and development in 2019 and is designated a Global Clinical Trial Delivery site – leading the delivery of more than 60 global clinical trials in oncology and respiratory disease.

For more information, please visit the company's website at www.astrazeneca.ca.



Roche

At Roche Canada, patients and science are at the heart of everything we do. With our combined strength in diagnostics and pharmaceuticals, we're driving personalized healthcare forward and adding our expertise in new areas, like artificial intelligence, real world data collection and analysis and collaborating with different sectors and industries.

Supporters Cont.



Seagen

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. Our pipeline is at various stages of testing and development. We are leveraging our antibody expertise to build a portfolio of proprietary ADCs and IO agents for hematologic malignancies and solid tumors.

For more information, please visit seagen.ca.



Sobi

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialized biopharmaceutical company, we provide sustainable medicines to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs.

For more information, please visit sobi.com/canada.




About the Organizer

Founded in 2009, Catalytic Health is one of Canada's largest medical education agencies and reaches over 50,000 Canadian clinicians a year with its educational programs, services and platforms.

As the largest independent medical publisher in Canada, our peer-reviewed open access scientific journals are a practical resource for Canadian healthcare practitioners, providing insights based on real-world experience.

Learn more about us at catalytichealth.com.



SHARE YOUR FEEDBACK & PRE - REGISTER FOR 2024!

Secure your spot at next year's event and tell us your thoughts on the 2023 Toronto Lymphoma Conference.

Scan the code to access the survey or visit:
<https://www.catalytichealth.com/tlc2023/feedback/>

